FindMyKOL
Clinical trialNCT02917629TerminatedPhase 2Interventional

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

SponsorNational Cancer Institute (NCI)Enrollment6Oral Cavity NeoplasmOropharyngeal NeoplasmStage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7Stage I Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7+8 more conditions
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from forming or coming back. The use of ACTOplus met XR may slow disease progression in patients with oral cavity or oropharynx cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore, Maryland, United States

  • University of Minnesota/masonic Cancer Center

    Minneapolis, Minnesota, United States

  • University of Rochester

    Rochester, New York, United States

  • University of Wisconsin Hospital and Clinics

    Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 May 2018
Primary completion
28 Aug 2019
Completion
28 Aug 2019
Last update posted
8 Mar 2023
Registered enrollment
6
Registry id
NCT02917629
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.